Machine Perfusion of Livers with Moderate Macrosteatosis: Efficacy of HOPE with Controlled Rewarming

Objective. To evaluate the efficacy of machine perfusion using hypothermic oxygenated perfusion (HOPE) with controlled rewarming in reducing ischemia-reperfusion injury of human donor livers with moderate macrosteatosis through comprehensive analysis of regulated cell death mechanisms.
Materials and methods. Prospective experimental study of 24 human donor livers with 30-50% macrosteatosis. Organs were randomized into three groups: control (standard cold storage, n=8), HOPE (hypothermic oxygenated perfusion at 10°C, n=8), and HOPE+W (HOPE with controlled rewarming from 10°C to 20°C, n=8). Markers of oxidative stress (MDA, GSH/GSSG), apoptosis (caspase-3, -7, -8, -9 activity, cytochrome c release), mitochondrial function (ATP production, respiratory function), inflammatory response (IL-1β, IL-6, TNF-α), and clinical transplantation outcomes were evaluated.
Results. The HOPE+W group achieved significant reduction in oxidative stress markers: MDA level was 2.8±0.4 vs 5.9±0.8 nmol/mg protein in controls (p<0.001), GSH/GSSG ratio was 5.2±0.6 vs 2.1±0.3 (p<0.001). Caspase-3 activity was reduced to 0.9±0.1 vs 2.4±0.3 rel.units in controls (p<0.001). ATP production was maintained at 18.2±2.1 vs 8.4±1.2 nmol/mg/min in controls (p<0.001). IL-6 concentration in perfusate was reduced to 45±7 vs 124±16 pg/ml (p<0.001). Peak ALT levels were 524±89 vs 1248±186 U/L in controls (p<0.001). Hepatic artery thrombosis was absent (0% vs 25% in controls, p=0.034). Graft survival without retransplantation was 100% vs 75% in controls (p=0.045).
Conclusion. Hypothermic oxygenated perfusion with controlled rewarming effectively protects livers with moderate macrosteatosis from ischemia-reperfusion injury through suppression of oxidative stress, preservation of mitochondrial function, inhibition of apoptosis, and modulation of inflammatory response, leading to significant improvement in early and medium-term transplantation outcomes.

1. Dutkowski P, Polak WG, Muiesan P, et al. First Comparison of Hypothermic Oxygenated PErfusion Versus Static Cold Storage of Human Donation After Cardiac Death Liver Transplants: An International-matched Case Analysis. Ann Surg. 2015;262(5):764-771. https://doi.org/10.1097/SLA.0000000000001473

2. Schlegel A, Muller X, Kalisvaart M, et al. Outcomes of DCD liver transplantation using organs treated by hypothermic oxygenated perfusion before implantation. J Hepatol. 2019;70(1):50-57. https://doi.org/10.1016/j.jhep.2018.10.005

3. van Rijn R, Karimian N, Matton APM, et al. Dual hypothermic oxygenated machine perfusion in liver transplants donated after circulatory death. Br J Surg. 2017;104(7):907-917. https://doi.org/10.1002/bjs.10515

4. Schlegel A, Mueller M, Muller X, et al. A multicenter randomized-controlled trial of hypothermic oxygenated perfusion (HOPE) for human liver grafts before transplantation. J Hepatol. 2023;78(4):783-793. https://doi.org/10.1016/j.jhep.2022.12.030

5. Ravaioli M, Germinario G, Dajti G, et al. Hypothermic oxygenated perfusion in extended criteria donor liver transplantation-A randomized clinical trial. Am J Transplant. 2022;22(10):2401-2408. https://doi.org/10.1111/ajt.17115

6. Kron P, Schlegel A, Mancina L, Clavien PA, Dutkowski P. Hypothermic oxygenated perfusion (HOPE) for fatty liver grafts in rats and humans. J Hepatol. Published online SepteTian X, Wang Y, Yuan M, et al. Heme Oxygenase-1-Modified BMMSCs Activate AMPK-Nrf2-FTH1 to Reduce Severe Steatotic Liver Ischemia-Reperfusion Injury. Dig Dis Sci. 2023;68(11):4196-4211. https://doi.org/10.1007/s10620-023-08102-0mber 21, 2017. https://doi.org/10.1016/j.jhep.2017.08.028

7. Patrono D, Surra A, Catalano G, et al. Hypothermic Oxygenated Machine Perfusion of Liver Grafts from Brain-Dead Donors. Sci Rep. 2019;9(1):9337. Published 2019 Jun 27. https://doi.org/10.1038/s41598-019-45843-3

8. Eden J, Brüggenwirth IMA, Berlakovich G, et al. Long-term outcomes after hypothermic oxygenated machine perfusion and transplantation of 1,202 donor livers in a real-world setting (HOPE-REAL study). J Hepatol. 2025;82(1):97-106. https://doi.org/10.1016/j.jhep.2024.06.035

9. Yamada N, Karasawa T, Wakiya T, et al. Iron overload as a risk factor for hepatic ischemia-reperfusion injury in liver transplantation: Potential role of ferroptosis. Am J Transplant. 2020;20(6):1606-1618. https://doi.org/10.1111/ajt.15773

10. Li Y, Feng D, Wang Z, et al. Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia/reperfusion. Cell Death Differ. 2019;26(11):2284-2299. https://doi.org/10.1038/s41418-019-0299-4

11. Tian X, Wang Y, Yuan M, et al. Heme Oxygenase-1-Modified BMMSCs Activate AMPK-Nrf2-FTH1 to Reduce Severe Steatotic Liver IschemiaReperfusion Injury. Dig Dis Sci. 2023;68(11):4196-4211. https://doi.org/10.1007/s10620-023-08102-0

12. Ni HM, Chao X, Kaseff J, et al. Receptor-Interacting Serine/Threonine-Protein Kinase 3 (RIPK3)-Mixed Lineage Kinase Domain-Like Protein (MLKL)-Mediated Necroptosis Contributes to Ischemia-Reperfusion Injury of Steatotic Livers. Am J Pathol. 2019;189(7):1363-1374. https://doi.org/10.1016/j.ajpath.2019.03.010

13. Roychowdhury S, McCullough RL, Sanz-Garcia C, et al. Receptor interacting protein 3 protects mice from high-fat diet-induced liver injury. Hepatology. 2016;64(5):1518-1533. https://doi.org/10.1002/hep.28676

14. Linkermann A, Bräsen JH, Darding M, et al. Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2013;110(29):12024-12029. https://doi.org/10.1073/pnas.1305538110

15. Kagan VE, Mao G, Qu F, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13(1):81-90. https://doi.org/10.1038/nchembio.2238

16. Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell. 2017;171(2):273-285. https://doi.org/10.1016/j.cell.2017.09.021

17. Wenzel SE, Tyurina YY, Zhao J, et al. PEBP1 Wardens Ferroptosis by Enabling Lipoxygenase Generation of Lipid Death Signals. Cell. 2017;171(3):628-641.e26. https://doi.org/10.1016/j.cell.2017.09.044

18. Olthoff KM, Kulik L, Samstein B, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl. 2010;16(8):943-949. https://doi.org/10.1002/lt.22091

19. Shabunin A.V., Loran O.B., Pushkar D.Yu., Veliev E.I., Minina M.G., Drozdov P.A., Astapovich S.A., Lidzhieva E.A. Hypothermic oxygenated perfusion in liver transplantation from expanded criteria donors. Russian Journal of Transplantology and Artificial Organs. 2024;26(2):63-72. (In Russ.) https://doi.org/10.15825/1995-1191-2024-2-63-72.

20. Boldyrev M.A., Grudinin V.N., Bogdanov V.K., Monakhov A.R., Gautier S.V. Combined sequential ex vivo perfusion of liver grafts from expanded criteria donors: a contemporary perspective. Russian Journal of Transplantology and Artificial Organs. 2025;27(2):189-211. . (In Russ.) https://doi.org/10.15825/1995-1191-2025-2-189-211